Acquired Bullous Disease

作者: Akiko Tanikawa , Masayuki Amagai

DOI: 10.1007/978-3-540-78814-0_36

关键词:

摘要: Pemphigus is a group of autoimmune blistering diseases that affect the skin and mucous membranes has three major forms: pemphigus vulgaris, foliaceus, paraneoplastic pemphigus. It characterized histologically by intraepi-thelial blister formation caused loss cell-to-cell adhesion keratinocytes (acan-tholysis) immunopathologically presence tissue-bound circulating IgG autoantibodies directed against cell surface or desmogleins. Desmogleins (Dsg1 Dsg3) are target antigens in pemphigus, clinical pheno-type correlated with patient's antides-moglein autoantibody profile. Paraneoplastic occurs association underlying neoplasms shows severe oral conjunctival erosions polymorphous eruptions. Paraneoplastic humoral (IgG autoan-tibodies Dsg3, Dsg1, plakin molecules), as well cellular, autoimmunity. Bulbous pemphigoid subepidermal disease most commonly elderly. The presentation typically pruritic eruption widespread tense blisters. It vivo bound C3 at dermoepidermal junction. The bullous BP230(BPAG1 BP230) BP180(BPAG2 type XVII collagen), which found hemidesmosomes along basement membrane zone. Epidermolysis acquisita rare acquired associated VII collagen, component anchoring fibrils. Systemic corticosteroids mainstay therapy for disease, adjuvant therapies, including immunosup-pressive agents, plasmapheresis, high-dose intravenous immunogloblin, biological used cases.

参考文章(103)
Rogers Rs rd, Bullous and cicatricial pemphigoid. Clinical, histopathologic, and immunopathologic correlations. Mayo Clinic proceedings. ,vol. 52, pp. 54- 66 ,(1977)
Jeffrey M Weinberg, Harry D Fischer, Boback Berookhim, Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis. ,vol. 74, pp. 245- 247 ,(2004)
Ernst H. Beutner, Vijay Kumar, Tadeusz P. Chorzelski, Immunopathology of the Skin ,(1987)
Barbara A. Gilchrest, David J. Leffell, Stephen I. Katz, Thomas B. Fitzpatrick, Lowell A. Goldsmith, Amy S. Paller, Klaus Wolff, Fitzpatrick's dermatology in general medicine. ,(1999)
M.J. Arin, A. Engert, T. Krieg, N. Hunzelmann, Anti‐CD20 monoclonal antibody (rituximab) in the treatment of pemphigus British Journal of Dermatology. ,vol. 153, pp. 620- 625 ,(2005) , 10.1111/J.1365-2133.2005.06651.X
I. Shimanovich, M. Nitschke, C. Rose, J. Grabbe, D. Zillikens, Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins British Journal of Dermatology. ,vol. 158, pp. 382- 388 ,(2007) , 10.1111/J.1365-2133.2007.08358.X
Cassian Sitaru, Mircea T. Chiriac, Sidonia Mihai, Jürgen Büning, Andreas Gebert, Akira Ishiko, Detlef Zillikens, Induction of Complement-Fixing Autoantibodies against Type VII Collagen Results in Subepidermal Blistering in Mice The Journal of Immunology. ,vol. 177, pp. 3461- 3468 ,(2006) , 10.4049/JIMMUNOL.177.5.3461
K.E. Harman, M.J. Gratian, B.S. Bhogal, S.J. Challacombe, M.M. Black, The use of two substrates to improve the sensitivity of indirect immunofluorescence in the diagnosis of pemphigus British Journal of Dermatology. ,vol. 142, pp. 1135- 1139 ,(2000) , 10.1046/J.1365-2133.2000.03538.X
Atsushi Takayanagi, Masayuki Amagai, Shinobu Gamou, Takashi Hashimoto, Russell P. Hall, Nobuyoshi Shimizu, Ken Ishii, Takeji Nishikawa, Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. Journal of Immunology. ,vol. 159, pp. 2010- 2017 ,(1997)
Stefan Beissert, Thomas Werfel, Uta Frieling, Markus Böhm, Michael Sticherling, Rudolf Stadler, Detlef Zillikens, Berthold Rzany, Nicolas Hunzelmann, Michael Meurer, Harald Gollnick, Thomas Ruzicka, Hans Pillekamp, Volker Junghans, Gisela Bonsmann, Thomas A. Luger, A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Pemphigus Archives of Dermatology. ,vol. 142, pp. 1447- 1454 ,(2006) , 10.1001/ARCHDERM.143.12.1536